mirabegron and Hypoxia

It has been established that obstructive sleep apnea (OSA) is an independent risk factor for atherosclerosis. Chronic intermittent hypoxia (CIH) activates sympathoadrenal system and upregulates β3 adrenergic receptor (β3 AR). However, the effect of selective β3 AR agonist mirabegron in CIH-induced atherosclerosis remains unknown.. We generated a CIH-induced atherosclerosis model through exposing ApoE. The expression of β3 AR was significantly elevated in CIH-induced atherosclerosis model. Furthermore, treatment with mirabegron (10mg/kg per day by oral administration for 6 weeks) ameliorated atherosclerosis in ApoE. This study first demonstrated that mirabegron impeded the progression of CIH-induced atherosclerosis, at least in part, via β3 AR-mediated oxidative stress, suggesting a promising therapeutic strategy for protecting against atherosclerosis induced by CIH.

Topics: Acetanilides; Animals; Apolipoproteins E; Atherosclerosis; Disease Models, Animal; Humans; Hypoxia; Mice; Oxygen; Reactive Oxygen Species; Receptors, Adrenergic; Sleep Apnea, Obstructive; Thiazoles